Sign up


Match Document Document Title
8962569 Compositions comprising spp24 peptide fragments  
Provided herein is tumor suppression composition and methods of making and using the same.
8962566 Multi-arm polymeric alkanoate conjugates  
Among other aspects, provided herein are multi-armed polymer conjugates comprising an alkanoate-linker, compositions comprising such conjugates, and related methods of making and administering the...
8962034 Antiviral therapy with a whole, leech saliva extract  
Methods are provided for isolating and using a whole-saliva leech extract. The methods can include feeding a phagostimulatory agent to a leech; inducing a regurgitation in the leech, the inducing...
8957185 MUC-1 cytoplasmic domain peptides as inhibitors of cancer  
Peptides from the MUC1 cytoplasmic domain and methods of use therefor are described. These peptides can inhibit MUC1 oligomerization, thereby preventing tumor cell growth, inducing tumor cell...
8957184 Pro-apoptotic peptides  
The invention relates to chimeric peptides useful as pro-apoptotic agents, for inhibition of in vitro cell proliferation and for treatment of tumors.
8957026 Beta-catenin targeting peptides and uses thereof  
The invention relates to β-catenin targeting peptides comprising an α-helical segment that are optionally stapled or stitched, and pharmaceutical compositions thereof. Uses of the inventive β...
8957014 Sensitization of tumor cells to radiation therapy through administration of endothelin agonists  
Methods to sensitize tumor cells to radiation therapy through the administration of an endothelin agonist such as the ETB agonist IRL1620.
8957027 Deacetylase inhibitor therapy  
The present invention relates to deacetylase inhibitor (e.g., histone deacetylase inhibitor) therapies and demonstrates that individuals with low electrolyte levels may have increased...
8957015 Tumor suppressor gene p47ING3  
The invention provides isolated nucleic acid and amino acid sequences of novel human tumor suppressors, antibodies to such tumor suppressors, methods of detecting such nucleic acids and proteins,...
8951975 ECT2 peptides and vaccines including the same  
Isolated peptides derived from SEQ ID NO: 42 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer...
8951971 Lymphatic zip codes in tumors and pre-malignant lesions  
Disclosed herein are compositions and methods for and involving selectively targeting tumor lymphatics.
8951972 FGFR1 extracellular domain combination therapies for lung cancer  
Methods of treating cancer comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one...
8946169 SPARC and methods of use thereof  
The invention provides methods for predicting or determining the response of a mammalian tumor to a chemotherapeutic agent and for treating a mammalian tumor comprising detecting and quantifying...
8946168 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin  
Screening and diagnostic reagents, kits and methods for primary and/or metastatic stomach or esophageal cancer are disclosed. Compositions for and methods of imaging and treating primary and/or...
8946291 Compositions and methods for treating pigmentary conditions and melanoma  
A method of treating melanoma in a subject comprising administering an amount of SOX9 sufficient to treat melanoma is disclosed. A method of treating a hyperpigmentary condition in a subject...
8946161 Method of treatment using stable liquid formulation of G-CSF  
Provided are pharmaceutical liquid formulations of G-CSF, which are stable over a long time period and substantially free of excipients, as well as ready-to-use syringes containing such...
8946159 Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment  
A combination therapy is provided and is directed to pharmaceutical compositions and methods for administering a combination of an α5β1 antagonist with an α2β1 antagonist to a subject. The met...
8945570 Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers  
The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and...
8945600 Methods of delivering pharmaceutical agents  
Provided are methods of delivering at least one pharmaceutical agent to the central nervous system (CNS) of a subject, methods of treating a neurological disorder or pain in a subject that include...
8946171 Immunization of an individual against carcinomas and the preliminary stages thereof  
The present invention relates to a pharmaceutical composition, comprising a cell cycle regulatory protein and/or an expressible nucleic acid coding for this in an amount suitable for immunization...
8946167 Pharmaceutical compositions containing plasma protein  
The invention is related to water-soluble products and pharmaceutical formulations in solid or liquid form mainly for parenteral use. They consist of or comprise a therapeutically active substance...
8945566 Methods for improving the bioactivity of therapeutic IgE antibodies for the treatment of disease  
The invention provides a method for increasing the bioactivity (e.g. the biosafety and efficacy) of a therapeutic IgE antibody of the invention in the treatment of a patient. Methods of the...
8945578 Method of treating cancer with an HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same  
Disclosed are: a peptide comprising an amino acid sequence composed of contiguous nine amino acid residues derived from a WT1 protein, wherein an amino acid residue at position 2 in the amino acid...
8940862 Selective anticancer chimeric peptides which bind transferrin receptor  
It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional...
8940695 Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy  
The present invention provide purified Flt4 receptor tyrosine kinase polypeptides and fragments thereof, polynucleotides encoding such polypeptides, antibodies that specifically bind such...
8940686 Cytokine  
A novel cytokine, U83A, is described, as are variant forms of the cytokine, having a wide range of agonistic and antagonistic activity against chemokine receptors. Uses of the chemokine in...
8940863 Selective anticancer chimeric peptides which bind neuropilin receptor  
It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional...
8940701 Compounds for, and methods of, treating cancer and inhibiting invasion and metastases  
Invasion-inhibiting peptides comprising either a modified cysteine (where the sulfur atom is modified with a alkyl group or other suitable group), and/or b) D-amino acids, for the treatment...
8940288 Method for treating cancer by administering IL-15 and IL-15Ralpha complexes  
The present invention relates to a therapeutic polypeptide and methods for its creation and use for modulating an immune response in a host organism in need thereof. In particular, the invention...
8940700 E-selectin compositions and use thereof for inducing E-selectin tolerance  
The invention relates to compositions and methods for treating or preventing vascular dementia in a mammal comprising mucosal administration of an amount of E-selectin polypeptide sufficient to...
8937039 Peptide-based peroxidase inhibitors and methods of using same  
The present invention provides peptide-based peroxidase inhibitors having the formula AA1-AA2-AA3, wherein AA1 is a positively charged, negatively charged or neutral amino acid, AA2 is a redox...
8933027 Method of treating a disease or condition characterised by aberrant epithelial cell proliferation  
A method is provided for treating a disease or condition characterized by aberrant epithelial cell proliferation and/or migration. One step of the method can include administering to a mammal an...
8933037 Methods involving PDGFRBETA inhibitors  
The invention refers to PDGFRbeta inhibitor for use in the antiproliferative treatment of T-cell lymphoma, in particular NHL, ALCL and PTCL.
8933031 Polypeptide inhibiting angiogenesis and application thereof  
Provided is a low molecular polypeptide that can inhibit angiogenesis consisting of amino acid sequence YRGKKA, which is same to one portion sequence in apolipoprotein (a) Kringle V. Also provided...
8933078 Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances  
A method for treating cancer is described using combination therapies comprising the use of hyperbaric oxygen with histone deacetylase inhibitors, with and without glycolytic therapies. The patient...
8932642 Treating prostate, ovarian, or breast cancer with a whole, leech saliva extract  
Methods are provided for isolating and using a whole-saliva leech extract. The methods can include feeding a phagostimulatory agent to a leech; inducing a regurgitation in the leech, the inducing...
8933038 Method of treating cancer with an HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same  
Disclosed are: a peptide comprising an amino acid sequence composed of contiguous nine amino acid residues derived from a WT1 protein, wherein an amino acid residue at position 2 in the amino acid...
8927500 Peptidomimetic macrocycles  
Provided herein are peptidomimetic macrocycles containing amino acid sequences with at least two modified amino acids that form an intramolecular cross-link that can help to stabilize a secondary...
8921305 Crotoxin administration for cancer treatment and pain relief  
Disclosed is a method for treating cancer and/or pain using an intra-patient dose escalation procedure to deliver dosages of crotoxin.
8921323 Methods and compositions for modulating BCL-2 family polypeptides  
The present invention is based, at least in part, on the identification of a novel active site on BCL-2 family polypeptide such as BAX, which when bound by a compound, modifies the activity of the...
8920800 Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins  
The present invention provides methods of treating a patient having a cancer comprising administering to the patient a soluble Fibroblast Growth Factor Receptor 1 (FGFR1) fusion protein such as an...
8920790 Uses of IL-12 in hematopoiesis  
Methods for enhancing or stimulating hematopoiesis including the step of administering Interleukin-12 (IL-12) to yield hematopoietic recovery in a mammal in need. Preferred methods include the step...
8921320 Targeted osmotic lysis of cancer cells  
A targeted osmotic lysis (TOL) of tumor cells that over-express voltage-gated sodium channels (VGSCs) has been developed that uses a combined therapy of a drug that blocks sodium,...
8920807 Vault complexes for cytokine delivery  
The invention relates to compositions of vault complexes containing recombinant cytokine fusion proteins that include a cytokine and a vault targeting domain, and methods of using the vault...
8920809 Chimera comprising bacterial cytotoxin and methods of using the same  
This invention provides, a recombinant polypeptide encoding a chimera. The chimera includes a DNase I fragment or a homologue thereof and a Cdt fragment or a homologue thereof. Further, the...
8916541 Synergistic combination of honokiol and modified citrus pectin in cancer therapy  
The invention comprises the administration of an amount of honokiol (HNK) and Modified Citrus Pectin (MCP) or similar pectin or alginate in amounts synergistic to inhibit cancer. The inhibition can...
8916161 Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins  
The present invention provides a method of treating BPH using modified pore-forming proteins (MPPs). These MPPs are derived from naturally occurring cytotoxic proteins (nPPs) that kill cells by...
8916681 Compound, use and method  
The present invention relates to the use of an antagonist of kisspeptin in the manufacture of a medicament for the treatment of a condition induced and/or worsened by kisspeptin activity in an...
8916517 Analogs of pituitary adenylate cyclase-activating polypeptide (PACAP) and methods for their use  
This invention relates to novel analogs of pituitary adenylate cyclase-activating polypeptide (PACAP), which are agonists for the PACAP/vasoactive intestinal peptide (VIP) receptors: PAC1, VPAC1...
8912136 Methods and compositions related to clot-binding compounds  
Disclosed are compositions and methods related to clot-binding compounds. For example, disclosed are compositions comprising a surface molecule and at least one modified clot-binding compound. The...